Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keros Therapeutics, Inc.KROS · Entity 6242 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keros Therapeutics, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,958 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Sale · Disposed 2,625 · Balance 10,958 F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 150,047 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 150,047 F3: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 102,233 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 102,233 F4: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.
F4: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2021 Filed Nov 3, 2021 23:04 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,346 | $42.45 | $99,587.70 |
DisclosureSEC source: 0001209191-21-062812 · doc4.xml · nonDerivative · entry 12 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 270,346 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.18 to $42.81 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 23:04 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,597 | $42.45 | $152,692.65 |
DisclosureSEC source: 0001209191-21-062812 · doc4.xml · nonDerivative · entry 11 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 399,257 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.18 to $42.81 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 23:04 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,957 | $41.65 | $164,809.05 |
DisclosureSEC source: 0001209191-21-062812 · doc4.xml · nonDerivative · entry 10 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 272,692 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.17 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 23:04 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 6,067 | $41.65 | $252,690.55 |
DisclosureSEC source: 0001209191-21-062812 · doc4.xml · nonDerivative · entry 9 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 402,854 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.17 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 23:04 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 991 | $43.04 | $42,652.64 |
DisclosureSEC source: 0001209191-21-062812 · doc4.xml · nonDerivative · entry 8 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 276,649 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.55 to $43.20 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 23:04 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,518 | $43.04 | $65,334.72 |
DisclosureSEC source: 0001209191-21-062812 · doc4.xml · nonDerivative · entry 7 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 408,921 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.55 to $43.20 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 23:04 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,120 | $42.10 | $89,252.00 |
DisclosureSEC source: 0001209191-21-062812 · doc4.xml · nonDerivative · entry 6 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 277,640 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.55 to $42.49 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 23:04 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,252 | $42.10 | $136,909.20 |
DisclosureSEC source: 0001209191-21-062812 · doc4.xml · nonDerivative · entry 5 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 410,439 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.55 to $42.49 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:04 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 4,797 | $42.43 | $203,536.71 |
DisclosureSEC source: 0001209191-21-062812 · doc4.xml · nonDerivative · entry 4 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 279,760 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.18 to $42.95 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:04 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 7,350 | $42.43 | $311,860.50 |
DisclosureSEC source: 0001209191-21-062812 · doc4.xml · nonDerivative · entry 3 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 413,691 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.18 to $42.95 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:04 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 4,599 | $41.85 | $192,468.15 |
DisclosureSEC source: 0001209191-21-062812 · doc4.xml · nonDerivative · entry 2 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 284,557 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 23:04 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 7,057 | $41.85 | $295,335.45 |
DisclosureSEC source: 0001209191-21-062812 · doc4.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 421,041 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8) and (9). F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| October 20, 2021 Filed Oct 21, 2021 20:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,463 | $38.31 | $56,047.53 |
DisclosureSEC source: 0001209191-21-061256 · doc4.xml · nonDerivative · entry 8 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 289,156 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.91 to $38.55 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| October 20, 2021 Filed Oct 21, 2021 20:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,242 | $38.31 | $85,891.02 |
DisclosureSEC source: 0001209191-21-061256 · doc4.xml · nonDerivative · entry 7 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 428,098 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.91 to $38.55 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| October 20, 2021 Filed Oct 21, 2021 20:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 148 | $37.55 | $5,557.40 |
DisclosureSEC source: 0001209191-21-061256 · doc4.xml · nonDerivative · entry 6 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 290,619 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.91 to $37.90 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| October 20, 2021 Filed Oct 21, 2021 20:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 229 | $37.55 | $8,598.95 |
DisclosureSEC source: 0001209191-21-061256 · doc4.xml · nonDerivative · entry 5 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 430,340 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.91 to $37.90 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 20:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 460 | $38.49 | $17,705.40 |
DisclosureSEC source: 0001209191-21-061256 · doc4.xml · nonDerivative · entry 4 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 290,767 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.37 to $38.74 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 20:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 704 | $38.49 | $27,096.96 |
DisclosureSEC source: 0001209191-21-061256 · doc4.xml · nonDerivative · entry 3 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 430,569 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.37 to $38.74 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 20:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,323 | $38.05 | $50,340.15 |
DisclosureSEC source: 0001209191-21-061256 · doc4.xml · nonDerivative · entry 2 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 291,227 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.37 to $38.36 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 20:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,029 | $38.05 | $77,203.45 |
DisclosureSEC source: 0001209191-21-061256 · doc4.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 431,273 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.37 to $38.36 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| October 18, 2021 Filed Oct 19, 2021 00:35 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 60 | $38.46 | $2,307.60 |
DisclosureSEC source: 0001209191-21-060784 · doc4.xml · nonDerivative · entry 12 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 292,550 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| October 18, 2021 Filed Oct 19, 2021 00:35 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 92 | $38.46 | $3,538.32 |
DisclosureSEC source: 0001209191-21-060784 · doc4.xml · nonDerivative · entry 11 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 433,302 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| October 18, 2021 Filed Oct 19, 2021 00:35 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 5,382 | $37.69 | $202,847.58 |
DisclosureSEC source: 0001209191-21-060784 · doc4.xml · nonDerivative · entry 10 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 292,610 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.36 to $38.30 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| October 18, 2021 Filed Oct 19, 2021 00:35 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 8,252 | $37.69 | $311,017.88 |
DisclosureSEC source: 0001209191-21-060784 · doc4.xml · nonDerivative · entry 9 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 433,394 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.36 to $38.30 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 00:35 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 60 | $40.60 | $2,436.00 |
DisclosureSEC source: 0001209191-21-060784 · doc4.xml · nonDerivative · entry 8 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 297,992 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 00:35 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 92 | $40.60 | $3,735.20 |
DisclosureSEC source: 0001209191-21-060784 · doc4.xml · nonDerivative · entry 7 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 441,646 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 00:35 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,199 | $39.44 | $47,288.56 |
DisclosureSEC source: 0001209191-21-060784 · doc4.xml · nonDerivative · entry 6 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 298,052 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.29 to $40.11 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 00:35 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,839 | $39.44 | $72,530.16 |
DisclosureSEC source: 0001209191-21-060784 · doc4.xml · nonDerivative · entry 5 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 441,738 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.29 to $40.11 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 00:35 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,977 | $38.95 | $77,004.15 |
DisclosureSEC source: 0001209191-21-060784 · doc4.xml · nonDerivative · entry 4 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 299,251 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.29 to $39.28 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 00:35 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,031 | $38.95 | $118,057.45 |
DisclosureSEC source: 0001209191-21-060784 · doc4.xml · nonDerivative · entry 3 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 443,577 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.29 to $39.28 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| October 14, 2021 Filed Oct 19, 2021 00:35 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,730 | $40.13 | $69,424.90 |
DisclosureSEC source: 0001209191-21-060784 · doc4.xml · nonDerivative · entry 2 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 301,228 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.71 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| October 14, 2021 Filed Oct 19, 2021 00:35 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,653 | $40.13 | $106,464.89 |
DisclosureSEC source: 0001209191-21-060784 · doc4.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 446,608 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.71 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7). F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 00:47 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,033 | $40.03 | $41,350.99 |
DisclosureSEC source: 0001209191-21-059749 · doc4.xml · nonDerivative · entry 6 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 302,958 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.14 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 00:47 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,584 | $40.03 | $63,407.52 |
DisclosureSEC source: 0001209191-21-059749 · doc4.xml · nonDerivative · entry 5 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 449,261 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.14 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 00:47 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,479 | $40.06 | $59,248.74 |
DisclosureSEC source: 0001209191-21-059749 · doc4.xml · nonDerivative · entry 4 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 303,991 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.33 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 00:47 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,267 | $40.06 | $90,816.02 |
DisclosureSEC source: 0001209191-21-059749 · doc4.xml · nonDerivative · entry 3 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 450,845 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.33 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| October 01, 2021 Filed Oct 6, 2021 00:47 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,496 | $40.16 | $100,239.36 |
DisclosureSEC source: 0001209191-21-059749 · doc4.xml · nonDerivative · entry 2 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 305,470 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5) and (6). F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| October 01, 2021 Filed Oct 6, 2021 00:47 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,827 | $40.16 | $153,692.32 |
DisclosureSEC source: 0001209191-21-059749 · doc4.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 453,112 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5) and (6). F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 20:39 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 6,532 | $42.29 | $276,238.28 |
DisclosureSEC source: 0001209191-21-058061 · doc4.xml · nonDerivative · entry 6 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 307,966 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.93 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 20:39 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 10,018 | $42.29 | $423,661.22 |
DisclosureSEC source: 0001209191-21-058061 · doc4.xml · nonDerivative · entry 5 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 456,939 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.93 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 20:39 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 13,233 | $41.52 | $549,434.16 |
DisclosureSEC source: 0001209191-21-058061 · doc4.xml · nonDerivative · entry 4 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 314,498 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.96 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 20:39 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 20,292 | $41.52 | $842,523.84 |
DisclosureSEC source: 0001209191-21-058061 · doc4.xml · nonDerivative · entry 3 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 466,957 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.96 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 20:39 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 17,854 | $40.51 | $723,265.54 |
DisclosureSEC source: 0001209191-21-058061 · doc4.xml · nonDerivative · entry 2 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 327,731 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5) and (6). F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 20:39 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 27,373 | $40.51 | $1,108,880.23 |
DisclosureSEC source: 0001209191-21-058061 · doc4.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 487,249 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5) and (6). F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 22:02 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,776 | $41.72 | $157,534.72 |
DisclosureSEC source: 0001209191-21-045620 · doc4.xml · nonDerivative · entry 10 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 345,585 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.51 to $42.00 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 22:02 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 5,789 | $41.72 | $241,517.08 |
DisclosureSEC source: 0001209191-21-045620 · doc4.xml · nonDerivative · entry 9 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 514,622 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.51 to $42.00 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 22:02 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 5,626 | $41.08 | $231,116.08 |
DisclosureSEC source: 0001209191-21-045620 · doc4.xml · nonDerivative · entry 8 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 349,361 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.51 to $41.50 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 22:02 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 8,627 | $41.08 | $354,397.16 |
DisclosureSEC source: 0001209191-21-045620 · doc4.xml · nonDerivative · entry 7 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 520,411 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.51 to $41.50 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 22:02 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 30 | $42.75 | $1,282.50 |
DisclosureSEC source: 0001209191-21-045620 · doc4.xml · nonDerivative · entry 6 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 354,987 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 22:02 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 46 | $42.75 | $1,966.50 |
DisclosureSEC source: 0001209191-21-045620 · doc4.xml · nonDerivative · entry 5 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 529,038 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.